Japanese pharmaceutical company Kyowa Hakko Kirin has announced the launch of its NESP injection 5μg plastic syringe as an additional formulation.
Kyowa Hakko Kirin has obtained initial approval for NESP in July 2007. The long-acting erythropoiesis stimulating agent has been highly recognized for its safety and efficacy for treating anemia of adult chronic kidney disease patients on / not on dialysis and is widely used in various medical institutions.
In September 2013, the company obtained additional approval for NESP for the indication of pediatric renal anemia in Japan. This approval for NESP is for use in renal anemia in pediatric and adult patients with chronic kidney disease.
According to Kyowa Hakko Kirin, the launch of NESP injection 5μg plastic syringe enables expansion of its NESP line-up. The company, with the new product launch, believes and hopes to contribute to meticulous, individually-targeted therapy of the patients suffering from anemia of chronic kidney disease.
The company will launch the NESP injection 5μg plastic syringe on 24 January 2014.
